Title: COMPARISON OF DIFFERENT PANCREATIC CANCER TREATMENTS: A
THREE-YEAR RETROSPECTIVE STUDY IN THE ONCOLOGY CENTER OF TANGIER
UNIVERSITY HOSPITAL, MOROCCO
Version: 0 Date: 17 Sep 2023
Reviewer's report:
Authors are reporting the results of a retrospective study about 55 patients treated for pancreastic
cancer, mostly metastatic(31) or locally advanced(15/55).
English have to be corrected
% have to be expressed with only one decimal
References number have to be reduced according to the journal recommendations, max 30 by
remonving the oldest one
Data concerning “median OS” are not convining and have to be corrected, specially due to
the short median follow up of 4.1 months and patients number specially in 2021 that’s less
than 20 collected. The paper contains this sentence “MOS was significantly longer within
patients treated with Folfirinox than Gemcitabine  at 6 versus 3 months, (p< 0.016). Median
OS within the patients that received Folforinox and Gemcitabine successively (19.7 months)
was significantly longer compared to Folforinox group or Gemcitabine group alone (p< 0.016).
This is in contradiction with literature data, the following “The median survival for patients with
untreated, locally advanced, unresectable pancreatic cancer is 8 to 12 months and only three to
six months for those with metastatic disease at presentation(Supportive care of the patient with
locally advanced or metastatic exocrine pancreatic cancer by Carlos Fernandez-del Castillo and
al,   Literature review in Aug 2023).
It's not a priority paper due to the reduced population
It needs a major revision and restructuration
Title: COMPARISON OF DIFFERENT PANCREATIC CANCER TREATMENTS: A
THREE-YEAR RETROSPECTIVE STUDY IN THE ONCOLOGY CENTER OF TANGIER
UNIVERSITY HOSPITAL, MOROCCO
Version: 0 Date: 17 Sep 2023
Reviewer's report:
Authors are reporting the results of a retrospective study about 55 patients treated for pancreastic
cancer, mostly metastatic(31) or locally advanced(15/55).
English have to be corrected
% have to be expressed with only one decimal
References number have to be reduced according to the journal recommendations, max 30 by
remonving the oldest one
Data concerning “median OS” are not convining and have to be corrected, specially due to
the short median follow up of 4.1 months and patients number specially in 2021 that’s less
than 20 collected. The paper contains this sentence “MOS was significantly longer within
patients treated with Folfirinox than Gemcitabine  at 6 versus 3 months, (p< 0.016). Median
OS within the patients that received Folforinox and Gemcitabine successively (19.7 months)
was significantly longer compared to Folforinox group or Gemcitabine group alone (p< 0.016).
This is in contradiction with literature data, the following “The median survival for patients with
untreated, locally advanced, unresectable pancreatic cancer is 8 to 12 months and only three to
six months for those with metastatic disease at presentation(Supportive care of the patient with
locally advanced or metastatic exocrine pancreatic cancer by Carlos Fernandez-del Castillo and
al,   Literature review in Aug 2023).
It's not a priority paper due to the reduced population
It needs a major revision and restructuration
Please review this paper.
user
Title: COMPARISON OF DIFFERENT PANCREATIC CANCER TREATMENTS: A
THREE-YEAR RETROSPECTIVE STUDY IN THE ONCOLOGY CENTER OF TANGIER
UNIVERSITY HOSPITAL, MOROCCO
Version: 0 Date: 17 Sep 2023
Reviewer's report:
Authors are reporting the results of a retrospective study about 55 patients treated for pancreastic
cancer, mostly metastatic(31) or locally advanced(15/55).
English have to be corrected
% have to be expressed with only one decimal
References number have to be reduced according to the journal recommendations, max 30 by
remonving the oldest one
Data concerning “median OS” are not convining and have to be corrected, specially due to
the short median follow up of 4.1 months and patients number specially in 2021 that’s less
than 20 collected. The paper contains this sentence “MOS was significantly longer within
patients treated with Folfirinox than Gemcitabine  at 6 versus 3 months, (p< 0.016). Median
OS within the patients that received Folforinox and Gemcitabine successively (19.7 months)
was significantly longer compared to Folforinox group or Gemcitabine group alone (p< 0.016).
This is in contradiction with literature data, the following “The median survival for patients with
untreated, locally advanced, unresectable pancreatic cancer is 8 to 12 months and only three to
six months for those with metastatic disease at presentation(Supportive care of the patient with
locally advanced or metastatic exocrine pancreatic cancer by Carlos Fernandez-del Castillo and
al,   Literature review in Aug 2023).
It's not a priority paper due to the reduced population
It needs a major revision and restructuration
assistant